Radiation Therapy With or Without Thalidomide in Treating Patients With

Status Completed

Clinical Trial Summary

Randomized phase III trial to compare the effectiveness of radiation therapy with or without thalidomide in treating patients who have brain metastases. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as thalidomide may stop the growth of brain metastases by stopping blood flow to the tumor. It is not yet known whether radiation therapy is more effective with or without thalidomide in treating brain metastases.

Clinical Trial Description

OBJECTIVES: I. Compare the overall survival of patients with multiple brain metastases treated with radiotherapy with or without thalidomide. II. Compare the time to tumor progression in patients treated with these regimens. III. Compare the time to neuro-cognitive progression in patients treated with these regimens. IV. Compare the cause of death distribution in patients treated with these regimens. V. Compare the frequency of toxic effects of these regimens in these patients. VI. Evaluate and compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to recursive partitioning analysis class (I vs II) and planned chemotherapy after whole brain irradiation (yes vs no). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients undergo radiotherapy once daily 5 days a week for 3 weeks. Arm II: Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily. Treatment with thalidomide continues for 2 years in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at completion of radiotherapy, and then every 2 months for 1 year. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 332 patients (166 per treatment arm) will be accrued for this study within 14.5 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00033254
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 3
Start date	March 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Completed	`NCT00098605` - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases	Phase 2
Completed	`NCT00072163` - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma	Phase 2
Completed	`NCT01703507` - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma	Phase 1
Active, not recruiting	`NCT01706432` - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Recruiting	`NCT01891318` - Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study	Phase 1/Phase 2
Suspended	`NCT01843413` - Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases	N/A
Completed	`NCT01276210` - Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases	Phase 1
Completed	`NCT01234740` - Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases	Phase 1
Completed	`NCT02312622` - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer	Phase 2
Terminated	`NCT00937482` - Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT02269111` - Quantitative MRI in Assessing Disease in Patients With Brain Tumors	N/A
Withdrawn	`NCT02277561` - Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery	N/A
Completed	`NCT00992602` - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer	Phase 2
Withdrawn	`NCT02145910` - Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms